Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer
Figure 1
Identification of circulating anti-LGALS3BP autoantibodies in the blood of cancer patients. (a) Western blot performed under reducing conditions. Purified LGALS3BP was separated by SDS-PAGE and transferred to nitrocellulose membrane. Gel stained in Coomassie brilliant blue detected two bands at about 97 KDa and 66 KDa, corresponding to the full length and cleaved form of the protein, respectively. Membrane was incubated with serum from healthy donors (controls) or patients affected by cancer and then processed in order to identify IgG antibodies. Membrane exposed to serum from patients, but not from controls, developed bands at the same size of LGALS3BP (arrows). (b) Quantification of serum LGALS3BP in healthy donors and cancer patients by ELISA. The bars represent the mean of 3 different assays in triplicate ± SD.
